Jennifer N. Perusini, Ph.D.; Chief Executive Officer
Dr. Jennifer Perusini, a neuroscientist and entrepreneur, is the Founder and Chief Executive Officer of Neurovation Labs. Dr. Perusini’s doctoral work forms the basis of Neurovation Labs’ pioneering research, which made the groundbreaking discovery that there is a physiological component to Post-Traumatic Stress Disorder (PTSD) that can be targeted to both diagnose and treat the disorder. Dr. Perusini and her team have developed a patent pending detection method and are currently creating a companion treatment for PTSD.
Dr. Perusini earned her B.A. in Neuroscience & Behavior at Barnard College, Columbia University, and her Ph.D. in Behavioral Neuroscience at the University of California, Los Angeles, where she studied the mechanisms underlying PTSD in an animal model. She completed her post-doctoral fellowship, which focused on rodent models of aging and Alzheimer’s disease, at Columbia University in the Departments of Psychiatry and Integrative Neuroscience.
Dr. Perusini has been a lecturer and teaching associate in the Psychology Departments at both UCLA and Barnard College and is on the Board of Directors of Women in Learning (WIL), a nationwide 501(c)(3) nonprofit organization dedicated to the support and advancement of women in science. She is a presenter at national biotech industry events, has been featured in numerous publications, and frequently speaks on issues pertaining to women entrepreneurs across industries.
Michael S. Fanselow, Ph.D.; Director of Research
Dr. Michael Fanselow is co-founder and Director of Research at Neurovation Labs. Dr. Fanselow received his B.S. in Psychology from CUNY Brooklyn College and his Ph.D. from the University of Washington in Biobehavioral Psychology. He received the Edwin B. Newman Award for Excellence in Research for his dissertation work there. Dr. Fanselow is a Professor in the Department of Psychology at University of California, Los Angeles and has held academic appointments at Rennselaer Polytechnic Institute and Dartmouth College before coming to UCLA in 1987. He has also received the Early Career Distinguished Scientific Contribution Award, the D. O. Hebb Award from the American Psychological Association, the Troland Award from the National Academy of Science, and is a member of the honorary Society of Experimental Psychologists. He was elected President of the American Psychological Association’s Division of Behavioral Neuroscience and Comparative Psychology and President of the Pavlovian Society.
Dr. Fanselow currently holds positions as the Staglin Family Chair and the Director of the Staglin Music Festival Center for Brain & Behavioral Health. His research focuses on the neurobiology of fear, anxiety & stress related behavior; he has developed the freezing assay of conditional fear, which has become one of the most widely-used tools in preclinical research of learning and memory in general, and fear and anxiety in particular. Dr. Fanselow’s lab has developed animal models of PTSD that capture several of the major components of this disorder, and he was Dr. Perusini’s graduate advisor. He has recently been appointed as Director of the Staglin Music Festival Center for Brain and Behavioral Health, whose mission is to conduct and facilitate research on the nature of mental disorders and develop pathways to restoring healthy brain function and adaptive behavior.
Richard P. Zemsky; Chief Operating Officer/ Legal
Richard P. Zemsky, an attorney and entrepreneur, is co-founder and Chief Operations Officer of Neurovation Labs. Mr. Zemsky received a B.S. in Mechanical Engineering from Villanova University before graduating from Columbia Law School. Richard has previously conducted research in heat transfer theory, shape memory alloy-based robotic design, and sediment accumulation on mid-ocean ridges, and served as team lead for mechanical and aeronautical design for a vertical take-off and landing electric aircraft.
As an attorney he focused on patent law across a range of technologies, advising early stage and established companies in the development, protection, and enforcement of their intellectual property rights. Mr. Zemsky is a presenter at national biotech and law conferences and has spoken on intellectual property panels as it pertains to the healthcare industry.
Daniel G. Marren; Chief Financial Officer
Daniel Marren is Chief Financial Officer of Neurovation Labs. Mr. Marren received his BBA in Accounting from the University of Notre Dame. He began his career in public accounting at Ernst & Whinney (now Ernst & Young) where he had a variety of international audit and consulting responsibilities, including IPOs for U.S. and foreign registrants. Subsequently, Daniel’s first startup was in 1988 and he has been active with startups and growth companies ever since, as a CEO, COO, CFO, consultant, investor, director, and/or adviser. Current and recent venture-backed activities and clients include FinTech, biotech, digital healthcare, hardware, wearable tech, SaaS, ecommerce, and certain insurance and reinsurance activities. Focusing on finance, operations, and strategy, he has helped to grow companies from conception to billion dollar operations.
Jeremy Bloomer; Advising Member
Jeremy Bloomer is on the Board of Directors of Neurovation Labs and is an advising member. Mr. Bloomer received his MBA in 1985 from The Amos Tuck School of Business Administration at Dartmouth College and a B.A. in 1980 from the University of Pennsylvania. He has over 20 years of investment banking, merchant banking, and investment management experience encompassing investment banking, research, sales, and trading in distressed securities, high yield securities, and private equity of emerging and middle market companies. He began his career in 1980 as a Commercial Loan Officer first at Chemical Bank and then Chase Manhattan Bank. Currently, Mr. Bloomer is the CEO and founder of the specialty finance company Greenwich Life Settlements, managing member of the Ivy Group, a NASD broker/dealer merchant bank he founded, and Vice Chairman of the Board of the New Fund Institute for Cancer Research. Previously, he was senior portfolio manager at the Airlie Group and co-founder of the boutique institutional investment bank Credit and Research & Trading, LLC (CRT).
Michael W. Wood, Ph.D.; Advising Member
Michael Wood is on the Board of Directors of Neurovation Labs and is an advising member. Dr. Wood received his B.S. in Environmental Health from Oakland University in 1992 and his Ph.D. in Pharmacology/toxicology from Duke University in 1996. Following postdoctoral appointments at Harvard and Eli Lilly, he worked in CNS drug discovery at AstraZeneca for 18 years, holding a variety of scientific positions – section head, project leader – before moving into strategic roles – target team leader and collaboration director. He has directed or facilitated dozens of drug discovery projects across a variety of CNS indications at all stages of discovery. He recently established an independent drug discovery consultancy, Neupharm LLC. He has held executive positions in with the American Society of Pharmacology and Experimental Therapeutics for the last eight years and recently co-organized a colloquium on academic drug discovery in collaboration with the Academic Drug Discovery Consortia.
Kevin S. Jones, Ph.D., Scientific Advisory Board Member
Kevin Jones is on the Scientific Advisory Board of Neurovation Labs. Dr. Jones holds a Ph.D. in Neuropharmacology from Duke University, and he is currently an Assistant Professor at University of Michigan Medical School in the Department of Pharmacology. His past and current affiliations include the Instituto Ramon y Cajal in Madrid, Spain; Johns Hopkins University Medical School; College of Osteopathic Medicine of the Pacific; University of Cincinnati; Pomona College; and Charles Drew University Medical School. Dr. Jones is an expert in drug discovery, and his vast body of work includes elucidating the neuropharmacology of psychiatric disorders and discovering new medicines for the treatment of PTSD, major depression and schizophrenia.